|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In Caucasians, the HSD3B2 (TG)n,(TA)n,(CA)n intron 3 length polymorphism is associated with both prostate cancer risk and aggressiveness and the SRD5A2 V89L polymorphism may modify the risk conferred by this polymorphism.
|
17823934 |
2007 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The authors found that prostate cancer was not associated with V89L (L allele vs. V allele: odds ratio = 0.99, 95% confidence interval: 0.94, 1.05) and was probably not associated with A49T (T allele vs. A allele: odds ratio = 1.10, 95% confidence interval: 0.86, 1.40).
|
19914946 |
2010 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer.
|
12210487 |
2002 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results indicate that the SRD5A2 V89L VV genotype interacts with VDR FokI TT/CT genotypes in NHW men and VDR CDX2 GG genotypes in HW men to increase the risk for prostate cancer.
|
18483391 |
2008 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, no clear consensus has been reached on the association between the SRD5A2 V89L, A49T and TA repeat polymorphisms and prostate cancer (PCa) risk.
|
21177315 |
2011 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We also found no evidence of a gene-gene interaction between CYP17 and SRD5A2 V89L polymorphisms on prostate cancer risk or endogenous steroid hormone levels.
|
11440959 |
2001 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The aim of the present study was to evaluate the distribution of polymorphisms for the androgen receptor (AR) (CAG, StuI, GGN), SRD5A2 (Ala49Thr, Val89Leu) and CYP17 (MspA1) genes that are considered to be relevant for risk of prostate cancer.
|
11847524 |
2002 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The CYP17 MspA1 I polymorphism has been associated with increased prostate cancer risk, and the SRD5A2 V89L polymorphism has been associated with low A-diol-g in Asian men, a serum marker of 5alpha-reductase activity.
|
11303586 |
2001 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our study suggests SRD5A2 V89L polymorphism could play a low-penetrant role in PCa risk among Europeans and individuals younger than 65 years.
|
19760631 |
2010 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Further studies of the V89L polymorphism may lead to better understanding of the etiology of pros</span>tate cancer metastases.
|
12042668 |
2002 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
CYP19 1531 C>T, SRD5A2 gene V89L, CYP17 gene -34 T/C, PSA-158 (G/A) regions were evaluated for the association between polymorphisms and benign prostatic hyperplasia and prostate cancer in study population.
|
26214411 |
2015 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The V allele of the V89L polymorphism in the SRD5A2 gene may dominantly increase the risk of prostate cancer.
|
12771801 |
2003 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thirty-three men with early onset prostate cancer (PCa) were genotyped for the SRD5A2 V89L substitution and other polymorphisms in genes encoding receptors or enzymes that play important roles in pathways of steroid metabolism to ascertain if they were associated with standard clinical measures of disease progression at the time of diagnosis.
|
18780294 |
2008 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Controversy exists over the significance of associations between the SRD5A2 (5alpha-reductase type 2) polymorphisms, A49T and V89L, and risk of prostate cancer.
|
17136762 |
2007 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
|
16039774 |
2005 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although there was no overall association between V89L and prostate cancer risk, A49T might play a role in the etiology of prostate cancer among Caucasians.
|
23277398 |
2013 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These data do not support a moderate to large effect of the SRD5A2 V89L polymorphism on plasma AAG levels or CaP risk in this predominantly Caucasian cohort, although a small effect cannot be completely excluded.
|
10606227 |
1999 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We exclude a role for the V89L polymorphism in conferring susceptibility to prostate cancer.
|
12869400 |
2003 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our data confirm in a large and homogeneous Caucasian French population that the low-activity V89L variant is associated with an increased risk of aggressive prostate cancer.
|
17448593 |
2007 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It was confirmed that in the population studied, the SRD5A2 V89L polymorphism was not associated with the risk of prostate cancer and SRD5A2 was not shown to be a key gene involved in prostate cancer development.
|
25310105 |
2014 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We evaluated the relationship of two single-nucleotide polymorphisms, A49T and V89L, with prostate cancer risk in a case-control study.
|
19215786 |
2009 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These observations have suggested that the CYP17 A2/A2, CYP1B1 Val/Val, and CYP2D6 genotypes may be associated with an altered risk of prostate cancer, while the CYP2D6 and SRD5A2 V89L polymorphism have no association with its risk in the North Indian population.
|
16716118 |
2006 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To provide etiological clues, we evaluated the relationships of four polymorphic markers in the SRD5A2 gene, specifically, A49T (a substitution of threonine for alanine at codon 49), V89L (a substitution of leucine for valine at codon 89), R227Q (a substitution of glutamine for arginine at codon 227), and a (TA)n dinucleotide repeat, with prostate cancer risk in a population-based case-control study in China, a population with the lowest reported prostate cancer incidence rate in the world.
|
11588134 |
2001 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Overall, the V89L variant was associated with prostate cancer; the OR for men with the leucine-leucine (LL) genotype compared to men with the valine-valine (VV) genotype was 4.47 (95% CI, 1.24-16.18).
|
16018939 |
2005 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results do not support the hypothesis that the V89L and A49T polymorphisms in the SRD5A2 gene are related to the risk of prostate cancer, but are compatible with the suggestion from earlier studies that men who are homozygous for the TA(9) or (18) alleles and men who have the TA(9)/TA(18) genotype are at a modestly reduced risk.
|
12712437 |
2003 |